The Trading Board

Sir Harpal is the Chair of our Trading Board and President of International Business and BioPharma at GRAIL. Prior to GRAIL, Sir Harpal was Senior Vice President and Head of Innovation EMEA at Johnson & Johnson. He spent over 15 years at Cancer Research UK, including 11 years as CEO, and was knighted in 2016. Earlier roles include CEO of The Papworth Trust and Nexan Group, and consultant at McKinsey & Co. He is an Honorary Fellow of the Academy of Medical Sciences, Royal College of Radiologists, Association of Cancer Physicians (UK) and St John’s College, University of Cambridge. He was also a previous non-exec director/trustee of UKRI and the Francis Crick Institute.

Gillian has over 30 years’ experience in the pharmaceutical industry. She serves as an independent director on four biotech Boards across Sweden, the UK, and North America, and as a strategic advisor to a private data company. She spent over 25 years at Merck & Co. in both regional and global roles spanning sales, marketing, market access, and business development, followed by executive leadership positions at Otsuka, UCB, and Roivant. Gillian is a member of the University of Newcastle Advisory Circle, supporting industry partnerships and fundraising.

Peter Chambré is a Trustee of Cancer Research UK and Chair of Cancer Research Horizons, the commercialisation arm of Cancer Research UK. He is also Chair of Immatics N.V., a biopharmaceutical company developing new cancer immunotherapy treatments. He has been a director of a number of public and private healthcare and life science companies, and was Chief Executive Officer of Cambridge Antibody Technology plc prior to its acquisition by AstraZeneca in July 2006.

Cristina is President (CEO) of Evinova, a global health tech business within the AstraZeneca group. Evinova provides clinical development AI enabled software for life-sciences in 54 countries. She was formerly Chief Digital Health Officer at AstraZeneca R&D covering all therapeutic areas. Cristina has held senior roles across commercial, finance, and consulting strategic transformation. A chartered accountant, she completed MIT’s Leading Enterprise Transformation program. Cristina contributes to digital health education at Cambridge University to prepare the next generation of innovators, clinicians and researchers to embrace digital in clinical development.

Andy is an entrepreneur and investor with a strong track record in founding and scaling life science, biotech, and healthtech ventures. He chairs Arecor Therapeutics, Congenica, Owlstone Medical, RNAvate and Ieso Digital Health, and advises funds including Cambridge Innovation Capital, UCLTF and the CRUK Seed Fund. Andy is a UKRI MRC Council member and Cambridge Angels founder. He was a founder and executive director of Chiroscience plc and has since founded, invested in and helped to scale over 30 innovative ventures including Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice.

Simon has over 40 years’ experience in the pharmaceutical industry and currently chairs four biotechnology companies in the UK, Switzerland, Belgium and United States. He is a Trustee of the Weizmann UK. Simon joined Kymab, a UK biotechnology company, as CEO in 2019, before selling it to Sanofi two years later. Before Kymab, Simon spent six years at Merck Group as COO of the healthcare division, with responsibility for global commercial organisation, global manufacturing, supply chain, as well as allergy and biosimilars businesses. He was also a member of the healthcare executive committee.